sPLA2-IB Level Correlates with Hyperlipidemia and the Prognosis of Idiopathic Membranous Nephropathy

Abstract

Recent studies suggested that serum secretory phospholipase A2 group IB (sPLA2-IB) was increased in idiopathic membranous nephropathy (IMN). However, the interference of high lipemia on the sPLA2-IB levels was not taken into account in these studies. The present study aimed to investigate the correlation between sPLA2-IB and lipemia, and the clinical merit of sPLA2-IB in the prediction of prognosis of IMN patients. A total of 64 IMN patients, 39 immunoglobulin A nephropathy (IgAN) patients and 64 healthy controls were included in the study. The levels of serum sPLA2-IB, lipemia and proteinuria were measured. Fifty IMN patients were followed up for 6 months. Pathologic stages were made for all IgAN and IMN patients. The results showed that the levels of serum sPLA2-IB, cholesterol and low-density lipoprotein cholesterol (LDL-C) were significantly higher, and the levels of albumin and high-density lipoprotein cholesterol (HDL-C) were significantly lower in IMN patients than in healthy controls and IgAN patients. Serum sPLA2-IB levels were also found to be higher in IgAN patients than in heathy controls, but the association of serum sPLA2-IB levels with proteinuria, cholesterol and albumin was only shown in IMN patients. Antibody against M-type receptor for secretory phospholipase A2 (PLA2R1) was positive in 81.3% IMN patients. Glomerular sPLA2-IB deposition, podocyte fused processes, and density deposition on thickened basement membrane were seen in IMN patients, but not in IgAN patients. IMN patients with lower sPLA2-IB and proteinuria levels were found to have better outcome after the 6-month follow-up. In IMN patients, sPLA2-IB levels were significantly increased in both serum and renal tissue. In conclusion, serum sPLA2-IB was closely correlated with proteinuria, albumin and cholesterol, and IMN patients with lower sPLA2-IB levels were more likely to achieve a better outcome.

Keywords

sPLA2-IB / lipemia / idiopathic membranous nephropathy / prognosis

References

[1] PolancoN, GutierrezE, CovarsiA, et al.. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol, 2010, 21(4): 697-704

[2] XiaofanH, JingX, ChenniG, et al.. New risk score for predicting progression of membranous nephropathy. J Transl Med, 2019, 17(1): 41

[3] TangL, YaoJ, KongX, et al.. Increasing prevalence of membranous nephropathy in patients with primary glomerular diseases: A cross-sectional study in China. Nephrology, 2017, 22(2): 168-173

[4] NieP, ChenR, LuoM, et al.. Clinical and Pathological Analysis of 4910 Patients Who Received Renal Biopsies at a Single Center in Northeast China. Biomed Res Int, 2019, 2019: 6869179

[5] BeckLJ, BonegioRG, LambeauG, et al.. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med, 2009, 361(1): 11-21

[6] LiW, GuoY, ZhangZ, et al.. Comparison of 2 Anti-PLA2R Immunoassays for the Diagnosis of Primary Membranous Nephropathy. Lab Med, 2018, 49(4): 316-322

[7] RadiceA, TrezziB, MaggioreU, et al.. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). Autoimmun Rev, 2016, 15(2): 146-154

[8] LiuNJ, ChapmanR, LinY, et al.. Phospholipase A2 as a point of care alternative to serum amylase and pancreatic lipase. Nanoscale, 2016, 8(23): 11834-11839

[9] GranataF, BalestrieriB, PetraroliA, et al.. Secretory phospholipases A2 as multivalent mediators of inflammatory and allergic disorders. Int Arch Allergy Immunol, 2003, 131(3): 153-163

[10] JoEJ, LeeHY, LeeYN, et al.. Group IB secretory phospholipase A2 stimulates CXC chemokine ligand 8 production via ERK and NF-kappa B in human neutrophils. J Immunol, 2004, 173(10): 6433-6439

[11] PeuravuoriHJ, FunatomiH, NevalainenTJ. Group I and group II phospholipases A2 in serum in uraemia. Eur J Clin Chem Clin Biochem, 1993, 31(8): 491-494

[12] LiW, ZhangM, GuoY, et al.. Serum secretory phospholipase A2 group IB correlates with the severity of membranous nephropathy. Clin Chim Acta, 2018, 482: 178-184

[13] PanY, WanJ, LiuY, et al.. sPLA2 IB induces human podocyte apoptosis via the M-type phospholipase A2 receptor. Sci Rep, 2014, 4: 6660

[14] HollieNI, KonaniahES, GoodinC, et al.. Group 1B phospholipase A(2) inactivation suppresses atherosclerosis and metabolic diseases in LDL receptor-deficient mice. Atherosclerosis, 2014, 234(2): 377-380

[15] CashJG, KuhelDG, GoodinC, et al.. Pancreatic acinar cell-specific overexpression of group 1B phospholipase A2 exacerbates diet-induced obesity and insulin resistance in mice. Int J Obes (Lond), 2011, 35(6): 877-881

[16] HollieNI, HuiDY. Group 1B phospholipase A(2) deficiency protects against diet-induced hyperlipidemia in mice. J Lipid Res, 2011, 52(11): 2005-2011

[17] HunsakerJ, La’UluSL, WynessSP, et al.. Lipemic interference of ceruloplasmin assays—An evaluation of lipid removal methods. Clin Chim Acta, 2018, 480: 71-78

[18] HoxhaE, HarendzaS, ZahnerG, et al.. An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant, 2011, 26(8): 2526-2532

[19] ZhangC, LiW, WenJ, et al.. Autophagy is involved in mouse kidney development and podocyte differentiation regulated by Notch signalling. J Cell Mol Med, 2017, 21(7): 1315-1328

[20] XiaoT, GuanX, NieL, et al.. Rapamycin promotes podocyte autophagy and ameliorates renal injury in diabetic mice. Mol Cell Biochem, 2014, 394(1–2): 145-154

[21] MoroniG, DepetriF, DelVL, et al.. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. Nephrol Dial Transplant, 2017, 32(10): 1691-1696

[22] Castro-CastroMJ, Candas-EstebanezB, Esteban-SalanM, et al.. Removing Lipemia in Serum/Plasma Samples: A Multicenter Study. Ann Lab Med, 2018, 38(6): 518-523

[23] YamaguchiM, AndoM, KatsunoT, et al.. Urinary protein and renal prognosis in idiopathic membranous nephropathy: a multicenter retrospective cohort study in Japan. Ren Fail, 2018, 40(1): 435-441

[24] BeckS, BeckG, OstendorfT, et al.. Upregulation of group IB secreted phospholipase A(2) and its M-type receptor in rat ANTI-THY-1 glomerulonephritis. Kidney Int, 2006, 70(7): 1251-60

[25] BeckLJ, SalantDJ. Membranous nephropathy: recent travels and new roads ahead. Kidney Int, 2010, 77(9): 765-770